{Reference Type}: Journal Article
{Title}: Malignant Superior Vena Cava Syndrome: A Scoping Review.
{Author}: Wright K;Digby GC;Gyawali B;Jad R;Menard A;Moraes FY;Wijeratne DT;
{Journal}: J Thorac Oncol
{Volume}: 18
{Issue}: 10
{Year}: 2023 10 3
{Factor}: 20.121
{DOI}: 10.1016/j.jtho.2023.04.019
{Abstract}: Malignant superior vena cava syndrome (SVCS) is a clinical problem that results from the obstruction of blood flow in the superior vena cava by an underlying malignancy. This may occur due to external compression, neoplastic invasion of the vessel wall, or internal obstruction with bland or tumor thrombus. Although symptoms are typically mild, SVCS can cause neurologic, hemodynamic, and respiratory compromise. Classic management options include supportive measures, chemotherapy, radiation therapy, surgery, and endovascular stenting. New targeted therapeutics and techniques have also recently been developed, which may have a role in management. Nevertheless, few evidence-based guidelines exist to guide treatment of malignant SVCS, and these recommendations are typically restricted to individual disease sites. Furthermore, there are no recent systematic literature reviews that address this question. Here, we present a theoretical case to frame this clinical problem and synthesize updated evidence published in the past decade relating to the management of malignant SVCS through a comprehensive literature review.